Urogen pharma ltd. (URGN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-37,793

-38,973

-22,252

-22,477

-21,444

-23,717

-20,532

-18,026

-13,382

-10,086

-298

-6,199

-3,417

Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization

82

108

65

60

63

68

58

51

240

58

17

87

45

Amortization/Accretion on marketable securities

-98

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

7,617

8,065

7,243

7,212

7,447

8,877

9,515

7,709

4,541

2,269

2,158

1,576

297

Exchange rate differences

-

-

-

-

-

-

0

0

-1

-

0

1

1

Fair value adjustment of warrants for preferred shares

-

-

-

-

-

-

-

-

-

0

0

277

-109

Realized loss on sale of short-term investment

-

-

-

-

-

0

0

0

-100

-

-

-

-

Amortization of right of use asset

374

292

245

246

245

-

-

-

-

-

-

-

-

Lease liability

361

290

246

201

173

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Decrease (increase) in inventory

-

-

-

-

-

0

-142

-207

33

179

-261

167

126

Decrease in accounts receivable

-

-

-

-

-

-

-120

228

4

-34

24

-12

-61

Increase in prepaid expenses and other current assets

518

-126

-562

1,041

41

11

-395

298

-232

48

206

150

158

Decrease in accounts payable and accrued expenses

-2,498

3,118

809

1,441

-2,440

2,147

636

1,628

-206

830

673

647

384

(Decrease) increase in deferred revenues

-

-

-

-

-

0

-86

-110

-454

350

-11

0

311

Decrease in employee related accrued expenses

-2,636

1,629

1,376

372

-1,591

2,241

473

920

-659

811

27

457

-32

Net cash used in operating activities

-35,635

-26,000

-12,528

-14,555

-17,934

-10,284

-9,279

-8,147

-9,624

-5,959

2,597

-3,461

-2,745

CASH FLOWS FROM INVESTING ACTIVITIES:
Sale of short-term investments

-

-

-

-

-

-

-

-

-35,901

-

-

-

-

Purchase of marketable securities

9,378

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

22,499

-

-

-

-

-

-

-

-

-

-

-

-

Change in restricted deposit

-

-

-

-

-

-

-

-

-

-100

100

1

4

Purchases of property and equipment

96

192

49

40

44

24

332

132

72

153

20

20

78

Net cash provided by (used in) investing activities

13,025

9,296

-12,659

-142,186

-44

-26

-333

-183

35,829

-36,054

-120

-21

-82

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options into ordinary shares

293

321

1,126

685

1,532

-

-

-

-

71

329

0

4

Issuance of ordinary shares, net of issuance expenses

-

0

0

-312

161,974

14

-14

-21

64,256

-

-

-

-

Issuance cost for shelf filing

203

-

-

-

-

-

-

-

-

-

-

-

112

Net cash provided by financing activities

90

245

1,126

373

163,506

2,200

-14

-21

64,256

-56

-399

62,148

-108

(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

-22,520

-16,459

-24,061

-156,368

145,528

-8,110

-9,626

-8,351

90,461

-42,069

2,078

58,666

-2,935

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash new lease liabilities

72

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash issuance cost

-

-

-

-

312

-

-

-

21

-

-

415

313

Exercise of options

-

-

-

-513

515

-

-

-

-

-

-

-

-